Australia isn't always the first place that investors look for technology leaders. But hidden among the bigger miners and banks are a handful of ASX tech stocks that are developing innovative solutions with the potential to win on the world stage.
Three that stand out today are named below. Here's what you need to know about them:
Image source: Getty Images
Catapult Sports Ltd (ASX: CAT)
Catapult Sports is a global leader in sports technology, providing wearable performance trackers and video analytics to professional teams. It already works with more than 4,600 teams across 40 sports in over 100 countries.
The ASX tech stock recently crossed a major milestone, with annual recurring revenue (ARR) topping US$100 million and free cash flow at a record US$8.6 million. Customer retention remains strong at 96%, and Catapult continues to add new clients across soccer, baseball, and basketball.
And with its Rule of 40 SaaS score rising to 31% and a strategy built on cross-selling new video solutions, Catapult looks increasingly like an Australian tech export to watch.
Gentrack Group Ltd (ASX: GTK)
Another ASX tech stock to watch is Gentrack. It provides mission-critical software to utilities and airports, helping them manage billing, operations, and customer experience. Its solutions are in demand as industries undergo rapid digital and sustainability transformations.
In its latest half-year results, revenue climbed nearly 10% to NZ$112 million, with recurring revenues up almost 17%. Importantly, the company is expanding globally, winning contracts with Utility Warehouse in the UK and major airport operators in Europe and the Middle East.
Management remains bullish on its prospects, forecasting full-year revenue of at least $230 million and mid-term growth above 15% annually. With utilities racing toward net zero and airports investing in digital infrastructure, Gentrack appears to be in the right place at the right time.
4DMedical Ltd (ASX: 4DX)
Finally, 4DMedical could be an ASX tech stock to keep an eye on. Its proprietary imaging technology provides doctors with a detailed, real-time view of lung function that traditional scans can't match.
The company has just secured U.S. FDA clearance for its CT-based ventilation-perfusion product (CT:VQ), marking a major step forward in commercialisation. This new tool offers a safer, faster, and more accurate way to assess pulmonary blood flow and airflow, with potential applications across conditions such as pulmonary embolism and chronic obstructive pulmonary disease.
And with lung disease a leading cause of death globally, the addressable market is huge, and 4DMedical is now positioned to build scale in the United States. This bodes well for its growth over the coming years.
